To read the full story
Related Article
- Japan Hypertension Society to Soon Report VART Paper Retraction in Publication
September 26, 2016
- British Medical Journal Retracts Sub-Analysis Paper of VART Study
December 11, 2014
- Prof. Komuro to Issue Objection to Chiba University in Wake of Second Retraction Request Related to VART Study
September 9, 2014
- Chiba Univ. Once Again Advises Authors to Withdraw Papers from VART Study
August 19, 2014
- Chiba University Weighs Asking University of Tokyo to Punish VART Chief Investigator
July 16, 2014
- Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”
July 16, 2014
- Chiba Univ. Advises Authors to Withdraw VART Papers
May 26, 2014
- Claims of Superior Cardiorenal Protective Effects of Diovan “Cannot Be Supported”: Outside Investigation of VART Study
April 30, 2014
- Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
- MHLW Panel Concludes Novartis Systematically Involved in Diovan Trials: Report
March 28, 2014
ACADEMIA
- Medical Society Says “No” to Discontinuation of Theodur Despite Supply Struggle
February 5, 2025
- Refusal to See Patients due to Kostaive Shots Might Violate “Duty of Care”: Lawyer
December 17, 2024
- Generic DPP-4s to Impact Diabetes Care and Health Finances, Potential Shortages a Concern
December 6, 2024
- Consortium on Pediatric Drug Development Up and Running from This Fiscal Year
November 25, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…